

**ONLINE APPENDIX: AUTHOR RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES  
(COMPREHENSIVE)—2017 ACC EXPERT CONSENSUS DECISION PATHWAY FOR PERIPROCEDURAL  
MANAGEMENT OF ANTICOAGULATION IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION**

<b>Committee Member</b>	<b>Employment</b>	<b>Consultant</b>	<b>Speakers Bureau</b>	<b>Ownership/ Partnership / Principal</b>	<b>Personal Research</b>	<b>Institutional, Organizational, or Other Financial Benefit</b>	<b>Expert Witness</b>
John U. Doherty, Chair	Jefferson Medical College of Thomas Jefferson University—Professor of Medicine	None	None	None	None	None	None
Ty J. Gluckman	Providence Heart and Vascular Institute—Medical Director	None	None	None	None	None	• Defendant, class action litigation related to diabetes, 2015*
William J. Hucker	Massachusetts General Hospital—Fellow in Cardiovascular Medicine	None	None	None	None	None	None
James L. Januzzi Jr.	Massachusetts General Hospital—Director, Dennis and Marilyn Barry Fellowship in Cardiology Research, Cardiology Division; Harvard Medical School—Hutter Family Professor of Medicine	<ul style="list-style-type: none"> <li>• Critical Diagnostics*</li> <li>• Novartis*</li> <li>• Phillips</li> <li>• Roche*</li> <li>• Sphingotec*</li> </ul>	None	None	• Provencio*	<ul style="list-style-type: none"> <li>• Amgen (DSMB)</li> <li>• Boehringer Ingelheim (DSMB)*</li> <li>• Janssen Pharmaceuticals, (DSMB)</li> </ul>	None
Thomas L. Ortel	Duke University Medical Center—Chief, Division of Hematology; Professor of Medicine and Pathology; Medical Director, Clinical Coagulation Laboratory	• Instrumentation Laboratories	None	None	None	None	None

Sherry J. Saxonhouse	Carolinas HealthCare System Sanger Heart & Vascular Institute— Cardiac Electrophysiology Associate Professor of Medicine	None	None	None	None	None	None
Sarah A. Spinler	University of the Sciences Philadelphia College of Pharmacy, —Professor of Clinical Pharmacy	<ul style="list-style-type: none"> <li>• AstraZeneca</li> <li>• Boehringer Ingelheim Pharmaceuticals, Inc</li> <li>• Daiichi-Sankyo</li> </ul>	None	None	None	None	None

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥\$5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

\*Significant relationship

†No financial benefit